Key Takeaways
- • BlueBox Asset Management, which oversees more than USD 3bn in AUM, promotes the BlueBox Precision Medicine Fund, a high-conviction global equity strategy launched in February 2023 that invests in companies developing or enabling precision medicine.
- • The fund, co-managed by Mark Dainty and Polina Suter, typically holds 25 to 45 stocks and is not constrained by any benchmark.
- • Per the article, the fund returned 31.3% net of fees in 2025, outperformed the S&P BMI Healthcare Index, and had an annualised return of 14.2% since inception as of March 2026.
- • The fund is classified as medium-high risk, with key risks including clinical trial failures, sector volatility, holding concentration and currency exposure for non-USD investors.
- • The article is a marketing communication from the manager, and it states that past performance is not an indication of future performance.
Summary
BlueBox Asset Management has published a promotional article on its BlueBox Precision Medicine Fund, which it describes as a targeted vehicle for the shift in healthcare toward genomics-driven, highly specific therapies. The firm manages more than USD 3bn in assets under management and also runs a separate technology strategy. The fund seeks long-term capital growth by investing globally in biotechnology, pharmaceutical and life sciences companies whose principal business is precision medicine. It is co-managed by Mark Dainty and Polina Suter, PhD.
The article argues that precision therapies, which target specific biological mechanisms, can improve economics for developers. According to the fund managers' analysis, success rates in drug development can be around three times higher, clinical trials can be shorter and development costs can be lower. The fund holds between 25 and 45 stocks with no benchmark constraint. Its portfolio pairs therapy developers, such as Argenx, Vertex Pharmaceuticals and Alnylam Pharmaceuticals, with enablers such as Natera, which provides diagnostics. Biotechnology is the majority exposure and the United States is the largest geographic weighting.
Performance figures cited in the article show a 31.3% net return in 2025, significantly ahead of the S&P BMI Healthcare Index, and cumulative returns of around 60% since the February 2023 launch, with annualised performance above 18%. The article also cites an annualised return of 14.2% since inception as of March 2026, and acknowledges recent volatility typical of biotech markets. Separate publisher context notes that the fund declined 9% in March, roughly in line with the S&P Select Biotechnology Index (-8.6%) but behind the S&P BMI Healthcare Index (-2.5%). The article describes the fund as medium-high risk and as behaving more like growth equity than a defensive allocation. It notes that past performance is not a reliable guide to future results and that the piece is a marketing communication.
The article argues that precision therapies, which target specific biological mechanisms, can improve economics for developers. According to the fund managers' analysis, success rates in drug development can be around three times higher, clinical trials can be shorter and development costs can be lower. The fund holds between 25 and 45 stocks with no benchmark constraint. Its portfolio pairs therapy developers, such as Argenx, Vertex Pharmaceuticals and Alnylam Pharmaceuticals, with enablers such as Natera, which provides diagnostics. Biotechnology is the majority exposure and the United States is the largest geographic weighting.
Performance figures cited in the article show a 31.3% net return in 2025, significantly ahead of the S&P BMI Healthcare Index, and cumulative returns of around 60% since the February 2023 launch, with annualised performance above 18%. The article also cites an annualised return of 14.2% since inception as of March 2026, and acknowledges recent volatility typical of biotech markets. Separate publisher context notes that the fund declined 9% in March, roughly in line with the S&P Select Biotechnology Index (-8.6%) but behind the S&P BMI Healthcare Index (-2.5%). The article describes the fund as medium-high risk and as behaving more like growth equity than a defensive allocation. It notes that past performance is not a reliable guide to future results and that the piece is a marketing communication.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.